We hypothesize that a combination of these two proteomic platforms in the context of a rigorous, clinically well-defined study design will significantly increase our ability to uncover proteomic blood signatures for downstream PSA reflex tests, thus improving prostate cancer diagnosis. This evidence concerns the gene KLK3 and prostate cancer.